Abstract
The surfaces of the abdomen and pelvis are an important anatomic site for the dissemination of gastrointestinal and gynecologic malignancy. This transcoelomic spread of cancer cells gives rise to peritoneal carcinomatosis which, without special treatments, is a fatal manifestation of these diseases. In order to control peritoneal carcinomatosis cytoreductive surgery to remove gross disease is combined with perioperative intraperitoneal and perioperative intravenous chemotherapy to eradicate microscopic residual disease. Chemotherapy agents are selected to be administered by the intraperitoneal or intravenous route based on their pharmacologic properties. A peritoneal- plasma barrier which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity results in a large exposure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration is facilitated by moderate hyperthermia (41-42°C) of the intraperitoneal chemotherapy solution. A constant dose of chemotherapy agent and volume of carrier solution based on body surface area allows prediction of systemic drug exposure and systemic toxicity. Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success.
Keywords: Intraperitoneal chemotherapy, 5-fluorouracil, doxorubicin, mitomycin C, peritoneal-plasma barrier, appendiceal cancer, colorectal cancer, peritoneal mesothelioma, ovarian cancer
Current Drug Discovery Technologies
Title: Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Volume: 6 Issue: 1
Author(s): Kurt Van der Speeten, Oswald Anthony Stuart and Paul H. Sugarbaker
Affiliation:
Keywords: Intraperitoneal chemotherapy, 5-fluorouracil, doxorubicin, mitomycin C, peritoneal-plasma barrier, appendiceal cancer, colorectal cancer, peritoneal mesothelioma, ovarian cancer
Abstract: The surfaces of the abdomen and pelvis are an important anatomic site for the dissemination of gastrointestinal and gynecologic malignancy. This transcoelomic spread of cancer cells gives rise to peritoneal carcinomatosis which, without special treatments, is a fatal manifestation of these diseases. In order to control peritoneal carcinomatosis cytoreductive surgery to remove gross disease is combined with perioperative intraperitoneal and perioperative intravenous chemotherapy to eradicate microscopic residual disease. Chemotherapy agents are selected to be administered by the intraperitoneal or intravenous route based on their pharmacologic properties. A peritoneal- plasma barrier which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity results in a large exposure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration is facilitated by moderate hyperthermia (41-42°C) of the intraperitoneal chemotherapy solution. A constant dose of chemotherapy agent and volume of carrier solution based on body surface area allows prediction of systemic drug exposure and systemic toxicity. Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success.
Export Options
About this article
Cite this article as:
Speeten Van der Kurt, Stuart Anthony Oswald and Sugarbaker H. Paul, Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy, Current Drug Discovery Technologies 2009; 6 (1) . https://dx.doi.org/10.2174/157016309787581084
DOI https://dx.doi.org/10.2174/157016309787581084 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Current Medicinal Chemistry Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology The Antioxidant Activities of Natural Polysaccharides
Current Drug Targets 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review)
Current Genomics Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics Treatment of Uterine Carcinomas
Current Cancer Therapy Reviews